{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:17:26Z","timestamp":1784614646171,"version":"3.55.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Institute of General Medical Studies","award":["5SC1GM116724-03"],"award-info":[{"award-number":["5SC1GM116724-03"]}]},{"name":"Anxiolytech"},{"name":"Pharmaceutical Research Center NIH","award":["1 C06-RR12512-01"],"award-info":[{"award-number":["1 C06-RR12512-01"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.pbb.2019.02.003","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T02:23:11Z","timestamp":1549938191000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy"],"prefix":"10.1016","volume":"179","author":[{"given":"Barbara A.","family":"Bricker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Peprah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye J.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0174-1153","authenticated-orcid":false,"given":"S.Y.","family":"Ablordeppey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.pbb.2019.02.003_bb0005","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.1016\/j.bmc.2008.06.030","article-title":"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one","volume":"16","author":"Ablordeppey","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"45","key":"10.1016\/j.pbb.2019.02.003_bb0010","doi-asserted-by":"crossref","first-page":"18488","DOI":"10.1073\/pnas.1104807108","article-title":"Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy","volume":"108","author":"Allen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.pbb.2019.02.003_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nn992","article-title":"Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice","volume":"6","author":"Anagnostaras","year":"2003","journal-title":"Nat. Neurosci."},{"issue":"9","key":"10.1016\/j.pbb.2019.02.003_bb0020","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.npp.1300940","article-title":"Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties","volume":"31","author":"Bardin","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2019.02.003_bb0025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1073\/pnas.0710487105","article-title":"The genetic design of signaling cascades to record receptor activation","volume":"105","author":"Barnea","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.pbb.2019.02.003_bb0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cell.2005.05.012","article-title":"An Akt\/beta-arrestin 2\/PP2A signaling complex mediates dopaminergic neurotransmission and behavior","volume":"122","author":"Beaulieu","year":"2005","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.pbb.2019.02.003_bb8000","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40263-016-0367-y","article-title":"Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis","volume":"30","author":"Bernagie","year":"2016","journal-title":"CNS Drugs"},{"issue":"7428","key":"10.1016\/j.pbb.2019.02.003_bb0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature11691","article-title":"Automated design of ligands to polypharmacological profiles","volume":"492","author":"Besnard","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pbb.2019.02.003_bb0040","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.2337\/diacare.27.8.2088-a","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement","volume":"27","author":"Boehm","year":"2004","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.pbb.2019.02.003_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020210","article-title":"Pharmacological blockade of serotonin 5-HT(7) receptor reverses working memory deficits in rats by normalizing cortical glutamate neurotransmission","volume":"6","author":"Bonaventure","year":"2011","journal-title":"PLoS One"},{"issue":"2\u20133","key":"10.1016\/j.pbb.2019.02.003_bb0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2009.09.019","article-title":"Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)","volume":"115","author":"Boter","year":"2009","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.pbb.2019.02.003_bb0055","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pbb.2012.05.003","article-title":"Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats","volume":"102","author":"Bricker","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2019.02.003_bb0060","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pbb.2014.02.013","article-title":"Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument","volume":"120","author":"Bricker","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2","key":"10.1016\/j.pbb.2019.02.003_bb0065","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00174869","article-title":"Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine","volume":"338","author":"Broekkamp","year":"1988","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"2\u20133","key":"10.1016\/j.pbb.2019.02.003_bb0070","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.schres.2005.04.010","article-title":"Clinicians' recognition of the metabolic adverse effects of antipsychotic medications","volume":"79","author":"Buckley","year":"2005","journal-title":"Schizophr. Res."},{"issue":"16","key":"10.1016\/j.pbb.2019.02.003_bb0075","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1021\/jm300603y","article-title":"Structure-functional selectivity relationship studies of beta-arrestin-biased dopamine D(2) receptor agonists","volume":"55","author":"Chen","year":"2012","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.pbb.2019.02.003_bb0080","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0893-133X(97)00176-0","article-title":"Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers","volume":"18","author":"Christoffersen","year":"1998","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2019.02.003_bb0085","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2019.02.003_bb0090","doi-asserted-by":"crossref","first-page":"246954","DOI":"10.1155\/2011\/246954","article-title":"Role of phosphorylation in the control of Clathrin-mediated internalization of GPCR","volume":"2011","author":"Delom","year":"2011","journal-title":"Int. J. Cell Biol."},{"issue":"2","key":"10.1016\/j.pbb.2019.02.003_bb0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjp.0707159","article-title":"F15063, a compound with D2\/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia","volume":"151","author":"Depoortere","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"47","key":"10.1016\/j.pbb.2019.02.003_bb0100","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1523\/JNEUROSCI.2999-05.2005","article-title":"Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action","volume":"25","author":"Diaz-Mataix","year":"2005","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.pbb.2019.02.003_bb0105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/schbul\/sbj055","article-title":"Treatment of schizophrenia negative symptoms: future prospects","volume":"32","author":"Erhart","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.pbb.2019.02.003_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/schbul\/22.1.15","article-title":"Clozapine eligibility among state hospital patients","volume":"22","author":"Essock","year":"1996","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.pbb.2019.02.003_bb0115","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jpsychires.2010.09.003","article-title":"Aripiprazole versus haloperidol treatment in early-stage schizophrenia","volume":"45","author":"Girgis","year":"2011","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.pbb.2019.02.003_bb0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00432133","article-title":"Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities","volume":"68","author":"Glennon","year":"1980","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.pbb.2019.02.003_bb0125","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1021\/jm00352a013","article-title":"Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane","volume":"25","author":"Glennon","year":"1982","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.pbb.2019.02.003_bb0130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00004714-199106000-00008","article-title":"An open trial of buspirone added to neuroleptics in schizophrenic patients","volume":"11","author":"Goff","year":"1991","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.pbb.2019.02.003_bb0135","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/WNR.0b013e328352de40","article-title":"5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux","volume":"23","author":"Huang","year":"2012","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/j.pbb.2019.02.003_bb0140","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0006-8993(99)02346-X","article-title":"The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens","volume":"858","author":"Ichikawa","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2019.02.003_bb0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1192\/bjp.172.1.35","article-title":"Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia","volume":"172","author":"Inskip","year":"1998","journal-title":"Br. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.pbb.2019.02.003_bb0150","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0028-3908(88)90134-7","article-title":"8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis","volume":"27","author":"Invernizzi","year":"1988","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.pbb.2019.02.003_bb0155","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.pbb.2019.02.003_bb0160","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","article-title":"Serotonin-dopamine interaction and its relevance to schizophrenia","volume":"153","author":"Kapur","year":"1996","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2019.02.003_bb0165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2005.02.005","article-title":"Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats","volume":"49","author":"Kleven","year":"2005","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2019.02.003_bb0170","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pbb.2019.02.003_bb0175","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nsmb.3014","article-title":"PRESTO-TANGO as an open-source resource for interrogation of the druggable human GPCRome","volume":"22","author":"Kroeze","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"2 Suppl","key":"10.1016\/j.pbb.2019.02.003_bb0180","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2019.02.003_bb0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.pbb.2019.02.003_bb0190","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.pbb.2019.02.003_bb0195","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/BF00439547","article-title":"Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction","volume":"97","author":"Liebman","year":"1989","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.pbb.2019.02.003_bb0200","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus","volume":"20","author":"Matsui-Sakata","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.pbb.2019.02.003_bb0205","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/sj.npp.1301098","article-title":"SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug","volume":"32","author":"McCreary","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl. 12","key":"10.1016\/j.pbb.2019.02.003_bb0210","first-page":"47","article-title":"Suicide and schizophrenia: clozapine and the InterSePT study. International Clozaril\/Leponex Suicide Prevention Trial","volume":"60","author":"Meltzer","year":"1999","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.pbb.2019.02.003_bb0215","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.semcdb.2007.07.001","article-title":"The interplay between clathrin-coated vesicles and cell signalling","volume":"18","author":"Mills","year":"2007","journal-title":"Semin. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.pbb.2019.02.003_bb0220","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00004714-199306000-00009","article-title":"Buspirone in the treatment of tardive dyskinesia","volume":"13","author":"Moss","year":"1993","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2019.02.003_bb0225","first-page":"123","article-title":"Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile","volume":"32","author":"Needham","year":"1996","journal-title":"Psychopharmacol. Bull."},{"issue":"7","key":"10.1016\/j.pbb.2019.02.003_bb0230","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives","volume":"11","author":"Newman-Tancredi","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"2\u20133","key":"10.1016\/j.pbb.2019.02.003_bb0235","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejphar.2008.02.005","article-title":"Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics","volume":"584","author":"Olsen","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.pbb.2019.02.003_bb0240","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2217\/pgs.10.50","article-title":"Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample","volume":"11","author":"Opgen-Rhein","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.pbb.2019.02.003_bb0245","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pbb.2010.12.011","article-title":"Behavioral, hyperthermic and pharmacokinetic profile of para-methoxymethamphetamine (PMMA) in rats","volume":"98","author":"Palenicek","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"3","key":"10.1016\/j.pbb.2019.02.003_bb0250","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.bmc.2011.12.019","article-title":"Multi-receptor drug design: haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents","volume":"20","author":"Peprah","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.pbb.2019.02.003_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00634146","article-title":"Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum","volume":"50","author":"Protais","year":"1976","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2019.02.003_bb0260","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0014-2999(86)90014-2","article-title":"Phenethylamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity","volume":"132","author":"Rasmussen","year":"1986","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2019.02.003_bb0265","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0091-3057(92)90464-Q","article-title":"Simple device for quantifying drug effects on the righting reflex","volume":"42","author":"Reeve","year":"1992","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2","key":"10.1016\/j.pbb.2019.02.003_bb0270","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1016\/S0014-2999(97)81951-6","article-title":"Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation","volume":"338","author":"Rollema","year":"1997","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.pbb.2019.02.003_bb0275","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-3223(00)00850-7","article-title":"5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex","volume":"48","author":"Rollema","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"23","key":"10.1016\/j.pbb.2019.02.003_bb0280","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pbb.2019.02.003_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med."},{"issue":"17","key":"10.1016\/j.pbb.2019.02.003_bb0290","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1016\/j.bmcl.2014.07.018","article-title":"Further evaluation of the tropane analogs of haloperidol","volume":"24","author":"Sampson","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.pbb.2019.02.003_bb0295","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","article-title":"Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile","volume":"425","author":"Schmidt","year":"2001","journal-title":"Eur. J. Pharmacol."},{"issue":"45","key":"10.1016\/j.pbb.2019.02.003_bb0300","doi-asserted-by":"crossref","first-page":"10117","DOI":"10.1523\/JNEUROSCI.3581-04.2004","article-title":"M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity","volume":"24","author":"Seeger","year":"2004","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.pbb.2019.02.003_bb0305","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1517\/17425255.1.3.377","article-title":"Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'","volume":"1","author":"Setola","year":"2005","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"6","key":"10.1016\/j.pbb.2019.02.003_bb0310","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","article-title":"3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro","volume":"63","author":"Setola","year":"2003","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.pbb.2019.02.003_bb0315","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2019.02.003_bb0320","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchromb.2005.03.024","article-title":"High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study","volume":"821","author":"Shimokawa","year":"2005","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"23","key":"10.1016\/j.pbb.2019.02.003_bb0325","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1016\/j.bmcl.2004.09.046","article-title":"Haloperidol: towards further understanding of the structural contributions of its pharmacophoric elements at D2-like receptors","volume":"14","author":"Sikazwe","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.pbb.2019.02.003_bb0330","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0091-3057(98)00110-5","article-title":"Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors","volume":"61","author":"Smith","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"5","key":"10.1016\/j.pbb.2019.02.003_bb0335","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0893-133X(99)00057-3","article-title":"Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation","volume":"21","author":"Sprouse","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.pbb.2019.02.003_bb0340","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2007.11.033","article-title":"World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia","volume":"100","author":"Tandon","year":"2008","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.pbb.2019.02.003_bb0345","doi-asserted-by":"crossref","first-page":"S420","DOI":"10.1016\/S0924-977X(08)70613-8","article-title":"P.3.c.029 incidence of tardive dyskinesia in patients receiving first or second generation antipsychotic therapy","volume":"18","author":"Tapp","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.pbb.2019.02.003_bb9000","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acschemneuro.7b00018","article-title":"Classics in Chemical Neuroscience: Haloperidol","volume":"8","author":"Tyler","year":"2017","journal-title":"ACS Chem. Neurosci"},{"issue":"50","key":"10.1016\/j.pbb.2019.02.003_bb0350","doi-asserted-by":"crossref","first-page":"20732","DOI":"10.1073\/pnas.1215489109","article-title":"Deletion of GSK3beta in D2R-expressing neurons reveals distinct roles for beta-arrestin signaling in antipsychotic and lithium action","volume":"109","author":"Urs","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2019.02.003_bb0355","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ceb.2013.11.002","article-title":"Integrated approaches to understanding antipsychotic drug action at GPCRs","volume":"27","author":"Urs","year":"2014","journal-title":"Curr. Opin. Cell Biol."},{"issue":"8","key":"10.1016\/j.pbb.2019.02.003_bb0360","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jmgm.2010.03.010","article-title":"Prediction of passive blood-brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors","volume":"28","author":"Vilar","year":"2010","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.pbb.2019.02.003_bb0365","series-title":"Nature Accelerated Article Preview","article-title":"Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone","volume":"2018","author":"Wang","year":"2018"},{"issue":"1","key":"10.1016\/j.pbb.2019.02.003_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-2187-9-1","article-title":"Multiple functions of G protein-coupled receptor kinases","volume":"9","author":"Watari","year":"2014","journal-title":"J. Mol. Signal."},{"issue":"2","key":"10.1016\/j.pbb.2019.02.003_bb0375","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pharmthera.2010.02.001","article-title":"The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action","volume":"126","author":"Wong","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pbb.2019.02.003_bb0380","author":"NIMH"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305718306312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305718306312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:34:56Z","timestamp":1758774896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305718306312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":78,"alternative-id":["S0091305718306312"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2019.02.003","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2019.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}